Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Factors, enablers and challenges for COVID-19 vaccine development.

Journal article

Excler J-L. et al, (2023), BMJ global health, 8

Vaccine access, equity and justice: COVID-19 vaccines and vaccination.

Journal article

Privor-Dumm L. et al, (2023), BMJ global health, 8

Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model

Journal article

Saunders JE. et al, (2023), eBioMedicine, 90, 104523 - 104523

Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

Journal article

Voysey M. et al, (2023), Clinical and Experimental Immunology, 211, 280 - 287

Booster Vaccination Against SARS-CoV-2 Induces Potent Immune Responses in People With Human Immunodeficiency Virus

Journal article

Fidler S. et al, (2023), Clinical Infectious Diseases, 76, 201 - 209

Lessons from the pandemic: Responding to emerging zoonotic viral diseases-a Keystone Symposia report.

Journal article

Cable J. et al, (2022), Annals of the New York Academy of Sciences

Immunogenicity of High-Dose MVA-Based MERS Vaccine Candidate in Mice and Camels

Journal article

Alharbi NK. et al, (2022), Vaccines, 10

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females

Journal article

Marchevsky NG. et al, (2022), eBioMedicine, 81, 104128 - 104128

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Journal article

Ogbe A. et al, (2022), JCI Insight, 7

Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility

Journal article

Rosadas C. et al, (2022), Journal of Virological Methods, 302, 114475 - 114475

Manufacturing a chimpanzee adenovirus-vectored SARS-CoV-2 vaccine to meet global needs.

Journal article

Joe CCD. et al, (2022), Biotechnology and bioengineering, 119, 48 - 58

ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models

Journal article

Lambe T. et al, (2021), Communications Biology, 4

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Journal article

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Journal article

Fischer RJ. et al, (2021), Nature communications, 12

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Journal article

Clemens SAC. et al, (2021), Nature Communications, 12

No one is safe until we are all safe

Journal article

Gilbert S. and Hatchett R., (2021), Science Translational Medicine, 13

Recombinant protein vaccines against SARS-CoV-2.

Journal article

Gilbert SC. and Lambe T., (2021), The Lancet. Infectious diseases, 21, 1337 - 1338

Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic.

Journal article

Hotez PJ. et al, (2021), EClinicalMedicine, 39

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.

Journal article

van Doremalen N. et al, (2021), Science translational medicine, 13

Transcriptomic profiling of dromedary camels immunised with a mers vaccine candidate

Journal article

Hala S. et al, (2021), Veterinary Sciences, 8

Load More